DRUG
HealthcareBright Minds Biosciences Inc.
$80.01
$-3.45 (-4.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Bright Minds Biosciences Inc. is a biotechnology company in the healthcare sector with 26 employees and a market capitalization of $623.05 million. The company's financial health is marked by significant losses, as indicated by a net income (TTM) of -$12,229,348. The gross margin, operating margin, and profit margin are all at 0.0%, suggesting that the company has not yet achieved profitability. The returns on equity and assets are also negative, standing at -27.9% and -18.8%, respectively. Meanwhile, the balance sheet shows a relatively low debt-to-equity ratio of 0.15, but a significant amount of cash on hand totaling $82.91 million. The valuation context is characterized by a forward P/E ratio of -13.61, which suggests that the market expects significant improvement in earnings. The price to book ratio stands at 10.24. The company does not pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Visit website →Key Statistics
- Market Cap
- $623.05M
- P/E Ratio
- N/A
- 52-Week High
- $97.75
- 52-Week Low
- $23.18
- Avg Volume
- 171.31K
- Beta
- -0.53
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 26